# Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

> **NCT07752550** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** Retlirafusp alfa+Nab-paclitaxel:
- **DRUG:** Retlirafusp alfa+Fluzoparib
- **DRUG:** Retlirafusp alfa+TP-AC
- **DRUG:** Retlirafusp alfa+Fluzoparib

## Key facts

- **NCT ID:** NCT07752550
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2028-07-30
- **Final completion:** 2029-07-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07752550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07752550, "Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07752550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*